Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Fox Corp Class A (FOXA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Fox Corp Class A — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while Fox Corp Class A trades at $54.12 (market cap $21.54B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Fox Corp Class A pays a 1.03% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | FOXA | |
|---|---|---|
Market Cap | $39.89B | $21.54B |
Sector | Health | Media |
52-Week High | $491.22 | $76.11 |
52-Week Low | $278.09 | $48.79 |
Enterprise Value | $38.15B | $25.51B |
Dividend Yield | — | 1.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
FOXA trades at $54.12, up 0.71% today, with a bearish technical signal despite recent earnings beats. The company reported strong 2025 results with revenue of $16.3B and net income of $2.26B, but faces headwinds from its $22B Roku acquisition. Analyst consensus remains positive with a $67.80 price target, though technical indicators show selling pressure near resistance at $55.
The outlook balances solid fundamentals against acquisition integration risks. FOXA's attractive valuation (P/E 14.24) and cash flow strength support upside potential, but investor sentiment is cautious due to leverage from the Roku deal. Near-term performance hinges on successful execution of streaming strategy amid industry consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Fox Corp Class A
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →
